Innovating for the healthcare needs of today and tomorrow



Q3 presentation, 14 November 2014



The global health scare

Reality

The reality we have to adress

"Multi resistant bacteria is a greater threat to mankind than climate change ..."

Professor Hans Rosling, Karolinska Institutet

"Antimicrobial resistance is so serious that it threatens modern medicine.


A post-antibiotic era in which common infections and minor injuries can kill – is a very real possibility for the 21st century."

WHO Global report on antimicrobial resistance, 2014





Patients with Healthcare Associated Infections



Source Sveriges Kommuner och Landsting (SKL), Sept 2014





The global health scare

Sweden


Targeting the most common HAIs and risks Bactiguard Infection Protection

Occurrence of HAI US (all hospital types)






Business expansion



Market expansion

Bactiguard is present in 51 geographical markets, with production facilities in Sweden and Malaysia





Highlights in the third quarter

- Somewhat slow quarter
- Negotiations with new government in Iraq
- Strengthening our sales and marketing organization
- Preparations and sales training in new markets South America, Middle East and India
- European market presence expanded to Portugal
- Market entry and initial delivery to Iran
- Pre-study with Maquet completed with positive results
- Further strengthening of financial position



Financial overview Highlights

Third Quarter (July-September 2014)


• Revenues of MSEK 28.1, minus 14% compared to 2013 (major delivery to Iraq in Q3 2013 affects comparison)


• EBITDA of MSEK 2.2 (4.7), margin 8% (14%)

Nine-month (January-September 2014)

• Revenues of MSEK 93.8, plus 13% compared to 2013


• EBITDA, excluding costs in connection with IPO, of MSEK 17.2 (14.8), an increase by 16 %, margin 18% (18%)







Financial overview Supplied products




- 12,000 BIP products supplied in Q3 compared to 62,000 during Q3 2013.
- During the first nine months of 2014 71,000 BIP products supplied compared to 86,000 corresponding period 2013.



Financial overview Revenue streams

Three revenue streams in the income statement





• From a product perspective Bactiguard has two lines of business, Licenses and the BIP portfolio, acknowledged in the accounts as three revenue streams



Financial overview Income distribution

Revenue distribution, Jul-Sep 2014





MSEK	Q3 2014	Q3 2013	Q1-Q3 2014
License revenues	24,3	21,3	69,6
Territorial fees	0,6	0,0	17,0
BIP products	0,5	10,4	2,1
Other revenue	2,6	0,8	5,1
Total revenues	28,1	32,5	93,8



Financial overview Key figures

Key figures	Jul-Sep	Jul-Sep	Jan-Sep
	2014	2013	2014
Revenues, SEKm	28,1	32,5	93,8
EBITDA, SEKm	2,2	4,7	14,2
EBITDA margin, %	8%	14%	15%
EBITDA*, SEKm	2,2	4,7	17,2
EBITDA margin*, %	8%	14%	18%
Operating profit, SEKm	-5,3	-2,9	-8,2
Net profit for the period, SEKm	-15,7	-5,1	-79,4
Operating cash flow**, SEKm	-21,8	0,5	-12,4


*EBITDA adjusted for IPO costs

**Cash flow from operating activities after investments and changes in working capital


- EBITDA (Q3) of MSEK 2.2, 8% EBITDA margin.
- EBITDA adjusted (Q1-Q3) MSEK 17.2, 18% EBITDA margin
- Net profit Q3 negatively affected by market valuation of bond of MSEK 6.8.
- Net profit Q1-Q3 negatively affected by IPO costs and market valuation bond totalling MSEK 48
- Operating cash flow Q3 MSEK -21.8 largely affected by payments related to the IPO



Financial overview Financial flexibility and strength







Interest costs, before and after issues and repurchases of bonds



Concluding remarks

- Healthcare associated infections and multiresistant bacteria some of the greatest challenges of our time
- Bactiguard has an efficient, safe and well proven solution for infection control
- Through the IPO we achieved a solid financial position and flexibility
- Stable platform in licensing business combined with attractive growth business
- Expanding our footprint, building sales & marketing capacity
- Well positioned for growth

